Shroff Eric 4

What Happened

• Eric Shroff, Senior Vice President at Abbott Laboratories (ABT), was granted equity on Feb 24, 2026: 10,873 performance-based restricted stock shares and 44,821 stock options. Both awards are reported at $0.00 per share (grant/award), so there was no cash purchase or sale.
• The 10,873 shares are a performance-based restricted stock award; the 44,821 units are an employee stock option grant (a derivative). These are compensation awards, not open-market trades.

Key Details

• Transaction date: February 24, 2026; Form 4 filed Feb 26, 2026 (appears timely).
• Amounts: 10,873 restricted shares (F1) and 44,821 options (F2); reported price $0.00 for both (typical for grants).
• Vesting/exercise schedule (per footnotes):
  • Restricted stock: 3-year performance-based award, with no more than one-third vesting in any year and vesting tied to a minimum return-on-equity target; shares may be withheld for taxes (F1).
  • Options: Become exercisable in three annual tranches — 14,940 on 2/24/2027, 14,940 on 2/24/2028, and 14,941 on 2/24/2029; granted under the Abbott 2017 Incentive Stock Program and exempt under Rule 16b-3 (F2).
• Shares owned after the transactions are not specified in the provided filing excerpt.
• Filing code: A (award/grant); no sale or purchase (no P or S codes). No indication of a cashless exercise or immediate sale.

Context

• These are compensation grants, which are common for executives and do not by themselves signal immediate buying or selling in the market. Performance RSAs vest only if performance targets are met; options vest over time before they can be exercised.
• For retail investors tracking insider activity, purchases are usually the clearest bullish signal. Grants like these mainly reflect compensation structure and retention incentives.